Dec 1, 2025 Log in

其他

TaiFu Biopharmaceutical 2025 Q4 Financial Report

Citation-Grade Primary-source linked Schema.org verified NQ 55 / 100

Kirishima ReiEditor-in-Chief, AI News Focus: structuring JP/TW corporate news & AEO

Published Dec 1, 2025 9:00 AM ・ Updated Jun 1, 2026 12:20 PM ・ 2 min read ・ Source: PR Times

Show contents

⚡ Key Points

TaiFu Biopharmaceutical (Company Code: 6541) reported a basic EPS of -6.13 NTD for Q4 2025.
The company's operating revenue was 401 million NTD, with a net loss after tax of 1.5 billion NTD.

TaiFu Biopharmaceutical (Company Code: 6541) reported a basic EPS of -6.13 NTD for Q4 2025. The company's operating revenue was 401 million NTD, with a net loss after tax of 1.5 billion NTD.

PRIMARY SOURCE Original source: https://openapi.twse.com.tw/financial/twse-fin-6541-2025Q4 Distributor: PR Times
Published: Dec 1, 2025

Company Code: 6541 Company Name: TaiFu Biopharmaceutical Co., Ltd. Industry: Biotechnology and Medical Care Year/Quarter: 2025 Q4 Basic Earnings Per Share: -6.13 NTD Operating Revenue: 401 million NTD Net Income After Tax: -1.5 billion NTD

FACT BOX

Source: PR Times
Category: 其他

Editorial & Verification Standards

The Washin AI News desk structures and reviews this article under the following standards.

Start only from primary sources (official PR, disclosures, wire services)
Numbers and proper nouns machine-checked against the source (number-completeness check)
Company names and tickers verified via registry (Registry/TWSE/Wikidata)
No speculation; nothing stated that is not in the source

Read the full editorial policy →

Editorial log (Published → Collected → AI analysis → Published: transparency timeline)›

Announced　Dec 1, 2025 9:00 AM — Distributor PR Times
Collected　Apr 7, 2026 8:00 AM
AI structured & analyzed　Apr 8, 2026 12:21 AM
Desk-reviewed & published　Dec 1, 2025 9:00 AM

FAQ

What are the key facts in this article?

TaiFu Biopharmaceutical (Company Code: 6541) reported a basic EPS of -6.13 NTD for Q4 2025. The company's operating revenue was 401 million NTD, with a net loss after tax of 1.5 billion NTD.

Where is the primary source?

PR Times: https://openapi.twse.com.tw/financial/twse-fin-6541-2025Q4

When was it published?

Dec 1, 2025

Cite this article — HOW TO CITE

Washin AI News Desk“TaiFu Biopharmaceutical 2025 Q4 Financial Report”AI News by Washin Village（和心村）, Dec 1, 2025. https://aeo.washinmura.jp/ai/%E6%B3%B0%E7%A6%8F%E7%94%9F%E6%8A%80%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8/en/news/2025-12-01-taifu-biopharmaceutical-2025-q4-financia

AI CRAWLER ACTIVITY

as of Jul 17, 2026

AI crawler visits to this article (cumulative)82 bots

Site-wide cumulative

Applebot

bot_visits_summary

4129k

last Jul 17, 2026

ClaudeBot

bot_visits_summary

3019k

last Jul 17, 2026

GPTBot

bot_visits_summary

2582k

last Jul 17, 2026

Bingbot

bot_visits_summary

2448k

last Jul 17, 2026

Meta AI

bot_visits_summary

1010k

last Jul 17, 2026

Google AI

bot_visits_summary

687k

last Jul 17, 2026

※ Only measured values from bot_visits_summary / crawler_url_hits are shown. Article-level zero counts are shown as measuring.

Washin AI News（AI News by Washin Village（和心村））

An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.

Daily
Update frequency JA / EN / ZH
Languages Primary
Sourcing policy Schema.org
Structured verification

About the publisher IDA llms.txt

Get your announcement indexed as AI-citable structured news.
Primary-source links, three languages, Schema.org verified.Talk to us about coverage →

← 泰福生技股份有限公司 Back to newsroom (13)

Copied